
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corp demonstrates a positive outlook due to expected revenue growth across both its core SET pulse oximetry business and advanced monitoring solutions, with specific projections indicating a 17% year-over-year increase in recognized contract revenue within the next 12 months. The company is also set to achieve EBIT margin expansion, anticipated to reach 29.2% and 29.8% in FY26 and FY27, respectively, as a result of strategic investments in advanced monitoring technologies and enhanced international market penetration. Additionally, with robust growth anticipated in both the pulse oximetry market and advanced monitoring platforms, Masimo's revenues are predicted to accelerate significantly over the long range plan as new product launches contribute to overall financial performance.
Bears say
Masimo Corp faces a challenging outlook due to anticipated declining operating margins, primarily driven by increased tariff impacts, with expectations of a $16M-$17M negative influence for FY25. Additionally, the company's revenue forecast has been revised downward for Q4 of 2025, indicating potential ongoing difficulties in sales performance and demand for its healthcare and capital equipment segments. The risks associated with unexpected negative announcements, competition, operational delays, and pricing pressures further contribute to the negative sentiment surrounding Masimo's long-term profitability and growth prospects.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares